{
  "study_id": "NCT01001377",
  "study_title": "Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study",
  "table_name": "Table 1",
  "table_title": "Baseline Patient Demographics",
  "description": "The provided document is an abstract and does not contain a patient demographics table. The information included here is derived from the text in the 'Findings' section, which states the number of patients who received each treatment.",
  "footnotes": [],
  "groups": [
    {
      "name": "Panitumumab",
      "n": 499,
      "type": "intervention"
    },
    {
      "name": "Cetuximab",
      "n": 500,
      "type": "intervention"
    }
  ],
  "characteristics": [
    {
      "original_label": "Patients who began study treatment",
      "standardized_name": "Total Patients",
      "category": "Sample Size",
      "time_point": "Baseline",
      "is_sub_characteristic": false,
      "group_data": [
        {
          "group_name": "Panitumumab",
          "data_type": "numeric_single",
          "value": 499.0,
          "raw_string": "499",
          "n_for_value": 499
        },
        {
          "group_name": "Cetuximab",
          "data_type": "numeric_single",
          "value": 500.0,
          "raw_string": "500",
          "n_for_value": 500
        }
      ]
    }
  ]
}